Supernus Pharmaceuticals Inc (SUPN)

May 25, 2026

SUPN PE Ratio & Valuation, Is SUPN Overvalued - Intellectia AI

May 25, 2026

May 24, 2026

Supernus CVR Milestone Triggers Cash Outflow And Undervalued Stock Debate - Yahoo Finance

May 24, 2026

May 22, 2026

Why Supernus Pharmaceuticals Shares Surged - AOL.com

May 22, 2026

May 20, 2026

Supernus Pharmaceuticals to make $33.4 million CVR milestone payment - Investing.com

May 20, 2026

May 20, 2026

Supernus Reaches Milestone, Triggers Contingent Value Rights Payment - TipRanks

May 20, 2026

May 20, 2026

According to a contingent value rights agreement, Supernus Pharmaceuticals Inc will pay Equiniti Trust Company $0.50 per share after achieving the first milestone. - Bitget

May 20, 2026

May 20, 2026

[8-K] SUPERNUS PHARMACEUTICALS, INC. Reports Material Event - Stock Titan

May 20, 2026

May 20, 2026

Three Growth Stocks Under Pressure: Supernus, RGA, and Black Stone MineralsNews and Statistics - IndexBox

May 20, 2026

May 19, 2026

Supernus Pharmaceuticals Q1 2026 earnings preview - MSN

May 19, 2026

May 16, 2026

Supernus Pharmaceuticals Q1 2026 Financial Results and Analyst Call HighlightsNews and Statistics - IndexBox

May 16, 2026

May 15, 2026

Trading Systems Reacting to (SUPN) Volatility - Stock Traders Daily

May 15, 2026

May 15, 2026

5 Revealing Analyst Questions From Supernus Pharmaceuticals’s Q1 Earnings Call - Yahoo Finance

May 15, 2026

May 15, 2026

SUPN Technical Analysis & Stock Price Forecast - Intellectia AI

May 15, 2026

May 13, 2026

Supernus Pharmaceuticals reports strong demand rebound after resolving supply constraints in March 2026 - Pluang

May 13, 2026

May 12, 2026

What to Know About This Fund’s Sale of a Pharma Stock Up 56% in a Year - Yahoo Finance

May 12, 2026

May 11, 2026

Supernus Pharmaceuticals (SUPN) Is Up 8.9% After Q1 Beat And Reaffirmed 2026 Outlook Has The Bull Case Changed? - Sahm

May 11, 2026

May 09, 2026

Supernus Pharmaceuticals (NASDAQ:SUPN) Upgraded to "Strong-Buy" at Wall Street Zen - MarketBeat

May 09, 2026

May 08, 2026

Supernus (SUPN) Q1 2026 Earnings Transcript - AOL.com

May 08, 2026

May 08, 2026

Supernus Pharmaceuticals Q1 Loss Narrows To US$0.04 EPS Challenging Persistent Bearish Narrative - Sahm

May 08, 2026

May 07, 2026

A Look At Supernus Pharmaceuticals (SUPN) Valuation After Strong Q1 Beat And Reaffirmed Guidance - Sahm

May 07, 2026

May 07, 2026

Why Supernus Pharmaceuticals (SUPN) Stock Is Up Today - The Globe and Mail

May 07, 2026

May 06, 2026

Supernus Pharmaceuticals Reports Strong Q1 2026 Results with 56% Revenue Growth - IndexBox

May 06, 2026

May 06, 2026

Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference - The Manila Times

May 06, 2026

May 06, 2026

Supernus offers May 12 webcast as CEO joins Bank of America event - Stock Titan

May 06, 2026

May 06, 2026

Does Q1 2026 Earnings Beat Reshape the Bull Case for Supernus Pharmaceuticals (SUPN)? - Yahoo Finance

May 06, 2026

May 06, 2026

Stifel Maintains Supernus Pharmaceuticals(SUPN.US) With Hold Rating, Maintains Target Price $55 - Moomoo

May 06, 2026

May 06, 2026

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q1 2026 Earnings Call Transcript - Insider Monkey

May 06, 2026

May 06, 2026

SUPN Q1 Deep Dive: Growth Products Drive Revenue Upside, Guidance Highlights Execution Challenges - The Globe and Mail

May 06, 2026

May 05, 2026

Supernus Pharmaceuticals Q1 Earnings Call Highlights - Yahoo Finance

May 05, 2026

May 05, 2026

Supernus outlines $840M-$870M 2026 revenue outlook as ONAPGO second-supplier filing targeted for Q3 - MSN

May 05, 2026

May 05, 2026

Supernus Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance

May 05, 2026

May 05, 2026

Supernus Pharmaceuticals | 8-K: Supernus Announces First Quarter 2026 Financial Results - Moomoo

May 05, 2026

May 05, 2026

Supernus (SUPN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance

May 05, 2026

May 05, 2026

Supernus Pharmaceuticals Q1 2026 Earnings Call Transcript - MarketBeat

May 05, 2026

May 05, 2026

Supernus Pharmaceuticals (SUPN) Beats Q1 Earnings and Revenue Estimates - Yahoo Finance

May 05, 2026

May 05, 2026

Supernus Pharmaceuticals (SUPN) Stock Rises on Q1 2026 Earnings - Quiver Quantitative

May 05, 2026

May 05, 2026

Earnings call transcript: Supernus Pharmaceuticals Q1 2026 revenue beats forecast - Investing.com Canada

May 05, 2026

May 05, 2026

Supernus Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 05, 2026

May 05, 2026

SUPERNUS PHARMACEUTICALS ($SUPN) Releases Q1 2026 Earnings, Stock Rises - Quiver Quantitative

May 05, 2026

May 05, 2026

Supernus: Q1 Earnings Snapshot - WKYC

May 05, 2026

May 05, 2026

Q1 2026 Supernus Pharmaceuticals Inc Earnings Call Transcript - GuruFocus

May 05, 2026

May 05, 2026

Four newer Supernus drugs bring in $149.1M as 2026 outlook holds - Stock Titan

May 05, 2026

May 05, 2026

[10-Q] SUPERNUS PHARMACEUTICALS, INC. Quarterly Earnings Report - Stock Titan

May 05, 2026

May 05, 2026

Supernus Pharmaceuticals’s (NASDAQ:SUPN) Q1 CY2026 Sales Beat Estimates - Yahoo Finance

May 05, 2026

May 05, 2026

Supernus (NASDAQ: SUPN) posts 39% revenue growth and reaffirms 2026 outlook - Stock Titan

May 05, 2026

May 05, 2026

Supernus Announces First Quarter 2026 Financial Results - marketscreener.com

May 05, 2026

May 05, 2026

BRIEF-Supernus Pharmaceuticals Q1 Product Sales USD 150.8 Million - TradingView

May 05, 2026

May 05, 2026

Supernus faces earnings test as Onapgo launch gains traction - Investing.com

May 05, 2026

May 05, 2026

Supernus faces earnings test as Onapgo launch gains traction By Investing.com - Investing.com Canada

May 05, 2026